Zhou, S.H., et al. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence. J Control Release, 2025 Jun 24, 385:113979.
0
By
In Saponin-Related Publications, Texto Cientifico
Posted

Zhou, S.H., et al. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence. J Control Release, 2025 Jun 24, 385:113979.

Zhou, S.H., et al. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence. J Control Release, 2025 [...]

READ MORE
 Patel, N., et al. Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates. Nat Commun, 2025 Jul 18, 16(1):6625.
0
By
In Saponin-Related Publications, Texto Cientifico
Posted

Patel, N., et al. Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates. Nat Commun, 2025 Jul 18, 16(1):6625.

Patel, N., et al. Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates. Nat Commun, 2025 Jul 18, [...]

READ MORE
 Scaria, P.V., et al. SARS-CoV-2 Receptor Binding Domain (RBD) Protein-Protein Conjugate Induces Similar or Better Antibody Responses as Spike mRNA in Rhesus Macaques. Vaccines (Basel), 2025 Jun 17, 13(6):648.
0
By
In Saponin-Related Publications, Texto Cientifico
Posted

Scaria, P.V., et al. SARS-CoV-2 Receptor Binding Domain (RBD) Protein-Protein Conjugate Induces Similar or Better Antibody Responses as Spike mRNA in Rhesus Macaques. Vaccines (Basel), 2025 Jun 17, 13(6):648.

Scaria, P.V., et al. SARS-CoV-2 Receptor Binding Domain (RBD) Protein-Protein Conjugate Induces Similar or Better Antibody Responses as Spike mRNA in Rhesus Macaques. Vaccines (Basel), 2025 Jun [...]

READ MORE
 Dagnew, A.F., et al. Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. Lancet HIV, 2025 Aug, 12(8):e546-e555.
0
By
In Saponin-Related Publications, Texto Cientifico
Posted

Dagnew, A.F., et al. Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. Lancet HIV, 2025 Aug, 12(8):e546-e555.

Dagnew, A.F., et al. Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 [...]

READ MORE